Mibefradil
From Wikipedia, the free encyclopedia
Systematic (IUPAC) name | |
---|---|
(1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate | |
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a607007 |
Legal status | Withdrawn from market |
Routes | Oral |
Identifiers | |
CAS number | 116644-53-2 |
ATC code | C08CX01 |
PubChem | CID 60662 |
DrugBank | DB01388 |
UNII | 27B90X776A |
KEGG | D08217 |
ChEMBL | CHEMBL45816 |
Chemical data | |
Formula | C29H38FN3O3 |
Mol. mass | 495.63 g/mol |
(what is this?) (verify) | |
Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.
It is nonselective.[1]
On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market,[2] due to the potential for drug interactions, some of them serious, which may occur when it is taken together with some other medications.
References
- ↑ Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
- ↑ Letter from Roche Laboratories: http://www.fda.gov/medwatch/SAFETY/1998/poscor.htm
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.